• Molecular imaging targeting the prostate-specific membrane antigen, somatostatin receptor subtype 2, and glycolytic pathway may further enhance our understanding of the heterogeneity of the neuroendocrine differentiation of prostate cancer in a non-invasive manner and on a whole-body scale. • Molecular imaging heterogeneity of the neuroendocrine differentiation of prostate cancer may have important implications on the selection of patients for radionuclide therapy. • Coexisting neuroendocrine differentiation of prostate cancer and adenocarcinoma of the prostate within one biopsy sample or across a patient further supports the use of molecular imaging to verify the biologic target expression on a whole-body scale.
- Neuroedocrine differentiation of prostate cancer
- Prostate-specific membrane antigen
- Radionuclide therapy
- Somatostatin receptor